Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single‐centre, prospective 1‐year observational cohort study of the first 100 patients treated

Sears, Alison; Woolf, Richard; Gribaleva, Elizaveta; Abdelrahman, Wedad; Robbie, Scott; Menon, Bina; Kirkham, Bruce; Smith, Catherine; Pink, Andrew E.

doi:10.1111/bjd.19631

Cited by 37 publications

(35 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Real-world evidence of the effectiveness and safety of dupilumab for atopic dermatitis Accumulating real-world evidence has ensured the effectiveness and tolerable safety of dupilumab both in the short term and in the long term. The articles searched in PubMed and Google Scholar are shown in Table 1 (Ariëns et al, 2020, Ariëns et al, 2021, Faiz et al, 2019, Fargnoli et al, 2020, Fargnoli et al, 2019, Jang et al, 2020, Jo et al, 2020a, Kreeshan et al, 2021, Matsutani et al, 2020, Nettis et al, 2020b, Nettis et al, 2020c, Olesen et al, 2019, Patruno et al, 2021a, Patruno et al, 2021b, Quint et al, 2020, Ribero et al, 2020, Sears et al, 2020, Tauber et al, 2019, Uchida et al, 2021, Uchida et al, 2019. Patruno et al reported the effectiveness and safety of dupilumab in elderly patients with AD in real life (Patruno et al, 2021a, Patruno et al, 2021b.…”

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Effectiveness and Safety Of Dupilumab For Atopic Dermatitis In The Real Worldmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

show abstract

“…The most prevalent side effects were eye-related while other side effects may have been a consequence of previous treatments, such as bruising from long-term corticosteroid use and itching following their withdrawal. Evidence of long-term clinical efficacy and safety of dupilumab in patients with AD has been established in real-world clinical practice [ 27 – 29 ]. A real-world study found disease severity was improved in 86% of patients, 30% had complete skin clearance [ 28 ], and 29% of adverse events were ophthalmic [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada

Ameen

Meller

Pinter

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction The Biologics in Atopic Dermatitis: Experiences & Learnings (BADEL) project aims to improve real-life understanding of how, where, and when biologics can play a role in the treatment of atopic dermatitis (AD) from the perspective of healthcare professionals (HCPs) and patients. Methods Individual experiences of 24 patients with moderate-to-severe AD and who had been treated with biologic therapy (dupilumab) for ≥ 3–6 months, and 20 HCPs with a sub-specialty interest in AD were collected by means of focus groups held in Canada, Germany, France, Italy and the United Kingdom. Dupilumab was the only biologic therapy available at the time of the study. Results Most patients had suffered from AD for many years, particularly from itch and psychosocial issues, with AD negatively impacting all aspects of their life. They had experienced a long treatment journey and seen many dermatologists, enduring treatment delays and failures. They had been prescribed various therapies without long-term success. Biologics provided symptom improvement, offering many patients a near-normal quality of life. Side effects, especially conjunctivitis, were the greatest drawback, and there were a few issues with incomplete or unreliable efficacy. HCPs agreed that biologic therapy for AD in the majority of patients demonstrated rapid onset, good efficacy and tolerability, and are a viable option in patients who had exhausted all other treatment options. However, those patients who failed to sufficiently respond or developed intolerable adverse effects, particularly ocular symptoms, require alternative therapeutic options. Conclusion Biologics can provide a near-normal quality of life for many patients with AD. Patients with AD who have failed conventional therapies should be offered all such novel therapies. Education and good patient–HCP communication will enable patients to manage their disease and treatment expectations. Patients and HCPs alike eagerly await alternative targeted therapies, which will offer greater choice and flexibility.

show abstract

“…Dupilumab is a monoclonal antibody targeting the common receptor of IL-4 and IL-13, two of the main cytokines promoting the Th2-type inflammation. 4 Dupilumab has shown remarkable activity in patients with atopic dermatitis, 4 and represents an emerging therapeutic option for eosinophil-mediated dermatoses, such as bullous pemphigoid. 5 In this patient, we found numerous IL-31 positive cells in the lesional skin, which were consistent with the intense pruritus referred by the patient.…”

Section: Dupilumab For the Treatment Of Recalcitrant Eosinophilic Dermatosis Of Haematologic Malignancymentioning

confidence: 99%

Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy

Maglie

Ugolini

Logu

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single‐centre, prospective 1‐year observational cohort study of the first 100 patients treated

Cited by 37 publications

References 8 publications

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada

Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy

Contact Info

Product

Resources

About